CCS1477, a first-in-class small molecule to treat prostate (CRPC) and other cancersP300/CBP bromodomain inhibitor CCS1477
CCS1477 inhibits the bromodomains of twin histone acetyl transferase proteins, p300/CBP
Other cancer tumours are also susceptible to p300/CBP inhibition, notably specific haematological, bladder and lung cancers.
Backed by strong pre-clinical data, CCS1477 is now heading to clinical trials.
CellCentric’s scientific foundation is in epigenetics. Having originally spun out of the University of Cambridge, the company has investigated over 50 epigenetic-related targets before focusing on p300/CBP.
Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond
Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer (CRPC)
Targeting the bromodomain of p300/CBP for the treatment of castrate resistant prostate cancer
Characterisation of CCS1477: A novel mall molecule inhibitor of p300/CBP for the treatment of CRPC
Novel small molecule inhibitors of p300/CBP down-regulate AR and c-Myc for the treatment of CRPC
A novel small molecule inhibitor of p300/CBP for the treatment of CRPC – preclinical evaluation
CellCentric’s team has deep experience of drug discovery and development in oncology
CellCentric raises $26 million to take first-in- class p300/CBP inhibitor into the clinic
May 15th 2018
CellCentric has raised $26 million in private financing to fund clinical testing of its first-in-class oncology drug candidate CCS1477. The funds will be used to test the novel p300/CBP inhibitor in late stage, treatment-resistant prostate cancer (up to Phase IIb). Recent data shared at AACR also highlighted the potential of CCS1477 in a range of cancers, and these will be explored additionally. The further funds come from one of CellCentric’s existing investors, Morningside Venture Investments.
CellCentric at AACR 2018: first-in-class p300/CBP inhibitor drug candidate, for prostate cancer and beyond
April 17th 2018
CellCentric’s oral drug candidate CCS1477 addresses the large and growing population of late stage prostate cancer patients who have inherent or acquired resistance to current second-line anti-androgen therapies. It can be used after or in combination with abiraterone (Zytiga), enzalutamide (Xtandi) and apalutamide (Erleada). New pre-clinical data is presented today at the annual American Association of Cancer Research (AACR) meeting, Chicago, supporting its targeted use not just for prostate cancer (CRPC), but also for other indications including certain haematological cancers (AML and multiple myeloma).
CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready for the clinic
March 7th 2018
Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials to investigate the novel drug’s tolerability and efficacy in treating late stage prostate cancer (CRPC). The active component is a p300/CBP bromodomain inhibitor that has a profound effect on the drivers of CPRC. It addresses the resistance seen in tumours treated with current second generation anti-hormonal drugs. Formulation and GMP manufacture of the capsules was carried out by Quay Pharma.
Nigel, Karen, Andrew & Neil will be at ASCO. CellCentric’s CCS1477 for prostate & other cancers pic.twitter.com/CSaOefL5sS
Collaboration has always been key to CellCentric. Best input > best output pic.twitter.com/CptzIch9C0
CCS1477 moving to the clinic for prostate cancer, plus Haems and tumours with p300 or CBP mutations pic.twitter.com/5kqXIjG1by